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Abbreviations 
AP, activator protein; ASK, apoptosis signal-regulating kinase; ATF, activating transcription 
factor; ATP, adenosine triphosphate; CNS, central nervous system; DEN, diethylnitrosamine; 
DMBA, 7,12-dimethylbenz[α]anthracene; ERK, Extracellular signal-regulated kinases; HCC, 
hepatocellular carcinoma; IKK, IκB kinase; IκB, inhibitor of inhibitor of kappa B; IL, interleukin; 
JIP, c-Jun-N-terminal kinase interacting protein; JNK, c-Jun-N-terminal kinase; MAPK, 
mitogen-activated protein kinase; MAP2K, mitogen-activated protein kinase kinase; MAP3K, 
mitogen-activated protein kinase kinase kinase; MEFs, murine embryonic fibroblasts; Myt, 
Myelin transcription factor 1; MM, multiple myeloma; NF-κB, nuclear factor κB; PARP14, 
Poly(ADP-ribose) polymerase family member 14; PUMA, p53 up-regulated mediator of 
apoptosis; SCC, squamous carcinoma cells; TCF4, transcription factor 4; TNF, tumor necrosis 
factor; TPA, 12-O-tetradecanoylphorbol-13-acetate; UV, ultraviolet. 
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ABSTRACT 
The c-Jun NH2-terminal kinases (JNKs) are master protein kinases that regulate many 
physiological processes, including inflammatory responses, morphogenesis, cell proliferation, 
differentiation, survival and death. It is increasingly apparent that persistent activation of JNKs 
are involved in cancer development and progression. Therefore, JNKs represent attractive 
targets for therapeutic intervention with small molecule kinase inhibitors. However, evidence 
supportive of a tumor suppressor role for the JNK proteins has also been documented. Recent 
studies showed that the two major JNK proteins, JNK1 and JNK2, have distinct or even 
opposing functions in different types of cancer. As such, close consideration of which JNK 
proteins are beneficial targets and more importantly what effect small molecule inhibitors of 
JNKs have on physiological processes are an absolute must. A number of ATP-competitive 
and ATP-noncompetitive JNK inhibitors have been developed, but have several limitations 
such as a lack of specificity and cellular toxicity. In this review we summarize the accumulating 
evidence supporting a role for the JNK proteins in the pathogenesis of different solid and 
hematological malignancies and discuss many challenges and scientific opportunities in the 
targeting of JNKs in cancer.  
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INTRODUCTION 
Protein kinases are the largest family of enzymes encoded by the human genome and have 
emerged as one of the most popular drug target class in the pharmaceutical industry (Zhang 
et al., 2009). The role of protein kinases is to catalyze the transfer of the terminal phosphoryl 
group of ATP to specific amino acid residues in target proteins (substrates). This modifies the 
functions of the target proteins by affecting either the activities or by controlling sub-cellular 
localization, degradation and association with other binding partners (Manning et al., 2002). 
Furthermore, protein kinases themselves can be activated by addition of phosphate groups to 
their specific amino acid residues either by an autophosphorylation event or phosphorylation 
by other kinases. Of these kinases, the mitogen-activated protein kinases (MAPKs) are a well-
studied family of serine-threonine kinases that plays an important regulatory role in the cell 
(Johnson and Lapadat, 2002). MAPKs are activated via a kinase signaling cascade in which a 
MAP kinase kinase kinase (MAP3K) activates a MAP kinase kinase (MAP2K) that in turn 
activates a MAP kinase (MAPK). There are three well-characterized subfamilies of MAPKs in 
mammals: the extracellular signal-regulated kinases (ERKs), the p38 kinases and the c-Jun 
NH2-terminal kinases (JNKs), and all three MAPKs have been conserved from unicellular 
organisms to complex organisms including humans (Johnson and Lapadat, 2002). 
 
The JNK kinase family includes three proteins (JNK1, JNK2 and JNK3) that are encoded by 
three separate genes jnk1 (Mapk8), jnk2 (Mapk9) and jnk3 (Mapk10), and are alternatively 
spliced to create at least ten variants of 46 and 55 kilodaltons (Davis, 2000). Whereas JNK1 
and JNK2 are expressed in most tissues, the expression of JNK3 is largely restricted to brain, 
heart and testes (Bogoyevitch and Kobe, 2006). The JNK proteins – also known as stress-
activated protein kinases (SAPKs) – similar to other MAPKs, are activated by a series of 
phosphorylation events (that is the MAP kinase module) in response to multiple stimuli such 
as cytokines, growth factors, pathogens, stress, toxins and drugs (Bogoyevitch and Kobe, 
2006; Seki et al., 2012) (Figure 1). MKK4 and MKK7 are the two MAP2K protein kinases that 
directly phosphorylate JNKs on threonine 183 (Thr183) and tyrosine (Tyr185) residues present 
in a conserved tripeptide motif (Thr-Pro-Tyr) within their activation loop (Davis, 2000). In turn, 
MKK4 and MKK7 are activated via dual phosphorylation by MAP3Ks, such as members of 
MEKK family, the mixed-lineage kinase family, the ASK family, TAK1 and TPL2 (Davis, 2000). 
Moreover, the kinase activity of JNKs is regulated by interaction with scaffold proteins 
(Whitmarsh et al., 2001) as well as dual-specificity phosphatases (Owens and Keyse, 2007) 
and NFκB transcription factors (Papa et al., 2006).  
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Upon activation by the upstream MAP2Ks, JNKs phosphorylate and active a number of 
nuclear and nonnuclear proteins, including the transcription factor activator protein-1 (AP-1), 
which is formed by dimerization of the Jun proteins (c-Jun, JunB, JunD) with the Fos proteins 
(c-Fos, FosB, Fra-1, Fra-2), activating transcription factor 2 (ATF-2), c-Myc, p53, Elk1, NFAT 
as well as cell death regulators of the Bcl-2 family in the mitochondria (Bogoyevitch and Kobe, 
2006). These proteins control a diversity of cellular responses, such as proliferation, 
differentiation, cell death and survival. 
 
The diversity of cellular functions of JNKs underscores the diversity of disease conditions in 
which JNKs are implicated, including cancer (Figure 2). Indeed, aberrant expression and 
activation of JNKs are found in many cancer cell lines as well as in patient samples (Wagner 
and Nebreda, 2009). Moreover, abnormalities in JNK activity have also been associated with 
diabetes (Hirosumi et al., 2002), inflammatory and neurodegenerative disorders (Roy et al., 
2004; Hunot et al., 2004). Consequently, the signaling mechanisms that underline JNKs 
expression and activities in these diseases and the identification of JNK inhibitory molecules 
are the subject of intense ongoing research. JNKs are also essential regulators of normal 
physiological functions such as immune responses and cell and tissue morphogenesis 
(Waetzig et al., 2005). Therefore, although targeting JNKs in the above diseases represents a 
worthwhile therapeutic strategy, inhibition of the JNK proteins could also be deleterious. Here, 
we particularly review the current knowledge on the role of JNK signaling pathways in cancer 
pathogenesis, with a focus on selected solid and hematological malignancies in which the 
progress in understanding their pathogenesis is proceeding at a rapid pace. We also offer a 
perspective on the principal challenges that are relevant to the development of drugs targeting 
JNKs. 
 
The role of JNKs in cancer 
The early findings that the transforming actions of several oncogenes such as Ras, c-fos, Met 
and Bcr-Abl could be JNKs dependent (Smeal et al., 1991; Rodrigues et al., 1997; Raitano et 
al., 1995; Behrens et al., 2000; Manning and Davis, 2003), suggested that the JNK signalling 
could contribute to the cellular transformation that supports cancer development. Indeed, c-
Jun, the prototypical downstream target of the JNK pathway, is required for transformation 
induced by the oncogene Ras (Lloyd et al., 1991) and for liver cancer development in mice 
(Eferel and Wagner, 2003; Min et al., 2012). Moreover, studies in a mouse model of intestinal 
cancer (Apcmin) have shown that the oncogenic function of c-Jun is dependent on 
phosphorylation by JNK as mice expressing a nonphosphorilatable mutant form of c-Jun 
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(JunAA/JunAA/Apcmin) developed smaller and fewer polyps (Nateri et al., 2005) thus implying 
a pro-oncogenic role for JNK/c-Jun axis in this context.  
In support of this view, hyperactivation of the JNK proteins themselves has been reported in 
multiple cancer cell lines and tissue samples (Hui et al., 2008; Chang et al., 2009a; Chang et 
al., 2009b; Barbarulo et al., 2012), and depletion of the individual JNKs can suppress 
tumorigenesis depending on the tissue specificity (Wagner and Nebreda, 2009). In primary 
hepatocellular carcinomas (HCCs), for example, activation of JNK1 but not JNK2 is increased 
as compared to the non-neoplastic lesions, and absence of JNK1 impaired liver cell 
proliferation and tumor formation (Hui et al., 2008; Chang et al., 2009a). Additionally, over-
activation of JNK1 in HCC tissues has been shown to associate with both a poor disease 
prognosis and expression of progenitor cell biomarkers (Chang et al., 2009b). JNK1 has also 
been shown to be an important contributor to the tumor-promoting activity of tobacco smoke in 
lung (Takahashi et al., 2010). In contrast, other studies have described an oncogenic function 
for JNK2 in various tumour-derived cell lines (Nitta et al., 2011; Bost et al., 1999; Yang et al., 
2003; Cui et al., 2006; Yoon et al., 2012) and animal cancer models (Chen et al., 2001; Ke et 
al., 2010; Chromik et al., 2007). Myeloma cell lines and primary tumors have been shown to 
exhibit elevated JNK2 activity, which appears to be the key determinant to enhanced cell 
survival (Barbarulo et al., 2012). Moreover, genetic deletion of JNK2 in mice reduced skin 
carcinogenesis induced by DMBA and TPA treatment (Chen et al., 2001), further outlining the 
role of JNK2 in tumorigenesis. In addition, a recent study established that both JNK1 and 
JNK2 are required for lung tumor formation induced by inactivation of endogenous KRas gene 
(Cellurale et al., 2011). These findings are consistent with the hypothesis that the JNK 
proteins may promote tumor development in a tissue- or cell-specific manner, and suggest 
that selective inhibition of these kinases may be effective in halting specific tumor formation. 
 
However, despite having a role in tumor development, a substantial body of evidence 
implicates JNK proteins in tumor suppression (Wagner and Nebreda, 2009; Davis 2000). In 
the DMBA/TPA-induced skin cancer model, for example, JNK1-null mice developed a greater 
number of papillomas compared to the wild-type mice (She et al., 2002), indicating that JNK1 
negatively regulates tumorigenesis. The tumor-suppressing function for JNK1 has been further 
supported by experiments, which demonstrated that JNK1-null mice are highly susceptible to 
tumor development after inoculation of both melanoma and lymphoma cell lines (Gao et al., 
2005). Moreover, JNK1-deficient mice spontaneously develop intestinal tumors (Tong et al., 
2007). It has been proposed that the tumor suppressor activity of JNKs results from their well 
recognized apoptotic functions involving the mitochondrial pathway (Davis 2000). Detailed 
analysis demonstrated that primary murine embryonic fibroblasts (MEFs) isolated from mice 
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that lack expression of both JNK1 and JNK2 proteins were resistant to the induction of 
apoptosis and failed to release pro-apoptotic molecules from mitochondria, including 
cytochrome C in response to UV-irradiation (Tournier et al., 2000). This indicates that stress-
induced JNK signaling leads to apoptosis via activation of the mitochondrial pathway. In line 
with these findings, studies in multiple myeloma cell lines showed that activation of the JNK 
pathway by 2-Methoxyestradiol (2ME2), a potent antitumor agent is associated with apoptosis 
and the release of Smac/DIABLO protein from mitochondria into cytosol (Chauhan et al., 
2003). Moreover, the activation of the JNK pathway is required for microtubule-damaging 
agent-induced apoptosis of breast cancer cells through its ability to phosphorylate and inactive 
the mitochondrial anti-apoptotic protein Bcl2 (Yamamoto et al., 1999; Srivastava et al., 1999). 
In addition, JNK2 has been shown to phosphorylate the tumor suppressor p53 on Serine 6, 
which is a key site for p53 stabilization and activation (Fuchs et al., 1998; Oleinik et al., 2007). 
Indeed, knockdown of JNK1 and JNK2 by siRNA impaired the p53-dependent apoptosis in 
response to anticancer drugs (Oleinik et al., 2007).  
 
In summary, the information outlined above indicate that JNK1 and JNK2 can act as either 
tumor promoter or as tumor suppressor kinases in different types of cancer and highlight the 
importance in understanding fully both the roles of JNKs and the molecular basis for these 
distinct functions in different tumors in order to validate the therapeutic potential of JNK 
inhibition. It has been proposed that differential regulation of specific cellular targets is the 
underlying mechanism for the distinct functions of JNK1 and JNK2 in cancer, although targets 
regulated by the individual JNK proteins remain largely unidentified (Figure 3). In the 
succeeding section, we focus on various cancers, both solid and hematological malignancies 
in which JNKs are reported to be involved and may be targetable. 
 
JNKs IN SOLID CANCERS 
Liver cancer 
Liver cancer is a compelling example of the involvement of the JNK pathway in the initiation 
and progression of cancer (reviewed by Seki et al., 2012). The most common type of primary 
liver cancer is hepatocellular carcinoma (HCC), with approximately 750,000 cases per year 
worldwide and few approved treatment options (Llovet et al., 2003; Jemal et al., 2011). HCC 
could arise from cirrhosis (scarring of the liver) or severe liver fibrosis caused by multiple 
rounds of hepatocyte death, inflammatory responses and compensatory liver regeneration, all 
of which involve overactivation of the JNK pathway in injured hepatocytes (Farazi and 
DePinho, 2006; Papa et al., 2009; Seki et al., 2012). Although exactly how the JNK pathway 
contributes to HCC development remains to be fully elucidated, evidence from studies in mice 
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with diethylnitrosamine (DEN)-induced HCC model suggests that the JNK pathway contributes 
to the development of HCC by inducing hepatocyte cell death that promotes compensatory 
proliferation (Seki et al., 2012). For example, deletion of the NF-κB activator IKKβ in 
hepatocytes induced activation of JNKs, cell death that triggers compensatory proliferation of 
surviving hepatocytes and greatly enhanced the development of HCC in response to DEN 
treatment (Maeda et al., 2005; reviewed by Papa et al., 2009). Interestingly, deletion of jnk1, 
but not jnk2 was able to completely abrogate the effect of deletion of IKKβ in hepatocytes on 
cell death, compensatory proliferation and hepatocarcinogenesis in response to DEN 
induction, indicating overactivation of JNK1 as a key player in DEN-induced HCC (Sakurai et 
al., 2006). This was further confirmed by studies using JNK1 deficient mice, which were much 
less susceptible to DEN-induced HCC development. This impaired formation of HCC was 
associated with decreased expression of the cell cycle regulator cyclin D and the vascular 
endothelial growth factor (VEGF), suggesting that JNK1 likely acts as a tumor-promoter in 
HCC by enhancing hepatocyte proliferation and neovascularization (Sakurai et al., 2006). The 
critical role for JNK1 activation in HCC was further supported by experiments which 
demonstrated that hepatocyte-specific deletion of NEMO/IKKγ, an activator of NF-κB, caused 
spontaneous formation of HCC in parallel with increased JNK1 activation, hepatocyte death 
and compensatory hepatocyte proliferation (Luedde et al., 2007). Additionally, administration 
of antioxidants to these mice resulted in significantly reduced JNK activation and HCC 
development, further indicating a role for JNK activation in promoting HCC formation (Luedde 
et al., 2007). JNK1 has also been shown to regulate the expression of the p53 up-regulated 
modulator of apoptosis (PUMA), a pro-apoptotic BH3-only protein, during fatty acid-induced 
hepatocyte apoptosis  (reviewed by Huang and Strasser, 2000; Cazanave et al., 2009). 
Indeed, in the DEN model, mice deficient in PUMA exhibit defects in HCC formation due to 
death and compensatory proliferation reduction of hepatocytes. Such effects were prevented 
in these mice by treatment with the JNKs inhibitor SP600125, indicating that the JNK1/PUMA 
axis plays a central role in DEN-induced hepatocyte apoptosis and subsequent proliferation 
(Qiu et al., 2011).  
 
A further proposed mechanism that accounts for the pro-tumorigenic role of JNK1 in HCC 
development is that JNK1 may regulate hepatocyte proliferation directly. In the DEN model, 
JNK1 was found to down-regulate the expression of the proliferation inhibitor p21 through 
transcriptional up-regulation of the growth promoter c-Myc (Hui et al., 2008). Mice that lack 
JNK1 display decreased tumor cell proliferation following DEN administration, and genetic 
inactivation of p21 in JNK1-deficient mice has been shown to restore hepatocyte proliferation 
in these mice. Furthermore, over-expression of c-Myc has been shown to increase 
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proliferation of JNK1-/- liver cells (Hui et al., 2008). In tissue samples from patients with HCC, 
JNK1, but not JNK2, has been reported to be constitutively active in more that 50% of 
samples studied relative to adjacent normal tissues (Hui et al., 2008; Chang et al., 2009a). 
The hyper-activation of JNK1 was associated with increased tumour size and an elevated 
expression of genes controlling cell cycle and proliferation, indicating the relevance of JNK1 
for the proliferation of liver cancer cells (Chang et al., 2009a). Indeed, knockdown of JNK1 by 
shRNA lentiviruses impaired cell proliferation in human HCC cell line, and JNK1 has been 
shown to reduce expression of p21 through up-regulation of c-Myc (Hui et al., 2008).  
 
More recently, an additional aspect has emerged, with relevance to the effects of the JNK 
signaling on HCC development. Davis and colleagues using mice with compound deficiency of 
JNK1 and JNK2 in hepatocytes demonstrated that JNKs have both tumor promoting and 
suppressing roles in hepatocarcinogenesis that depend on the cell types of the liver. The 
authors generated a genetically engineered mouse model deleted of JNK1 in hepatocytes and 
JNK2 in the entire organism, and discovered that these mice developed more HCCs than wild-
type mice following administration of DEN. The increased HCC development was associated 
with increased hepatocyte death, and, consequently increased compensatory proliferation as 
well as increased c-Myc and c-Jun expression. This indicates that JNK activity in hepatocytes 
functions to reduce tumor development (Das et al., 2011). However, in nonparenchymal cells 
of liver, such as hepatic immune cells (Kupffer cells), JNK activity is reported to promote HCC 
development. The authors went further to demonstrate that this was mediated through 
creation of an inflammatory environment, including the expression of pro-tumorigenic 
cytokines such as IL6 and TNFα that contribute to compensatory hepatocyte proliferation (Das 
et al., 2011).  
 
To date, JNK1 inhibitors have not been developed to treat patients with HCC. Nevertheless, 
the functional roles of JNK1 in hepatocyte death and compensatory proliferation make drugs 
of this type promising anti-HCC therapies. Indeed, an inhibitory peptide directed against the 
substrate-docking domain of JNK proteins (D-JNKI1) was shown to suppress JNK activity and 
reduce tumor growth in the DEN-induced HCC model and in human HCC xenograft model 
(Hui et al., 2008). In a rat DEN-induced HCC model, the administration of the JNKs inhibitor 
SP600125 reduced the number and size of HCCs (Nagata et al., 2009). Additionally, inhibition 
of JNK activity has been shown to improve the efficacy of some current chemotherapeutics. 
For example, SP600125 in combination with the chemotherapy drug TNF-related apoptosis 
inducing ligand (TRAIL) was shown to increase apoptosis in human HCC cultures (Mucha et 
al., 2009). Indeed, activated JNK1 was found in tissue samples from patients with HCC (Hui et 
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al., 2008) and correlates directly with poor therapeutic response to sorafenib, a multikinase 
inhibitor that is currently being tested in clinical trials for HCC (Hagiwara et al., 2012). 
Therefore, collectively, the findings described above have illustrated the importance of JNK1 
in promoting HCC and the potential of JNK1 to be a target, alone or in combination with other 
therapeutics, for anti-HCC therapies. 
 
Breast cancer 
In sharp contrast to tumor-promoting role of JNK1 described above, in breast cancer models 
the JNK pathway has been shown to suppress tumor development. One example came from 
the work of Cellurale and colleagues (Cellurale et al., 2010). They employed mice 
heterozygous for the p53 tumor suppressor, which spontaneously develop breast cancer in a 
pattern and frequency similar to that reported for the Li-Fraumeni breast cancer in humans 
(Kuperwasser et al., 2000). It has been shown that the crossing of p53-/+ mice with JNK1-/- 
mice and JNK2-/- mice causes significantly shortened tumor-free survival compared with 
control p53-/+ mice, suggesting that JNK1 and JNK2 may function to reduce breast cancer. A 
similar tumor-suppressing role for JNK proteins, especially JNK2, was also observed in 
transgenic mice that express the polyomavirus (PyV) middle T (MT) oncogene in mammary 
epithelial cells (Webster et al., 1998). PyV MT transgenic mice develop multifocal mammary 
tumors, which frequently metastasize to the lung, thus emulating both early and late stages of 
human breast cancer. Systemic deletion of JNK2 in PyV MT transgenic mice was found to 
shorten latency and increase tumor multiplicity. Interestingly, PyV MT/jnk2-/- mammary tumors 
showed more genomic instability, aneuploidy and impaired DNA damage response due to a 
reduction of DNA repair proteins and activation of the cell-cycle inhibitor p21, suggesting that 
in this case JNK2 expression prevents breast cancer development by regulating cell cycle 
progression and DNA repair mechanisms (Chen et al., 2010). Further evidence for the tumor-
suppressing role of JNKs in breast cancer has been provided from studies that show 
compound JNK deficiency in mammary epithelial cells to promote tumor formation in a 
KRas/p53 mouse model of breast cancer (Cellurale et al., 2012). In line with these findings, 
inactivating mutations in the JNK activator Mkk4 gene have been identified in human breast 
cancer (Su et al., 1998; Su et al., 2002). In addition, deletion of Mkk7 gene (the other 
upstream activator of JNK) in primary murine epithelial cells facilitates oncogenic 
transformation in the mammary gland (Schramek et al., 2011), further validating the tumor-
suppressive role of the JNK cascade in breast cancer. Activation of the JNK pathway has also 
been shown to mediate the cytotoxic effects of the chemotherapy drug taxol in MCF7 breast 
cancer cells (Mamay et al., 2003). Whilst these recent findings implicate the JNK cascade in 
mammary carcinoma suppression, they also emphasize that JNK1 and JNK2 have redundant 
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or at least overlapping roles. Inducing both JNK1 and JNK2 would therefore be exploited for 
therapeutic benefit in patients with breast cancer. 
 
Skin cancer 
Persistent ultraviolet (UV) radiation exposure is the major cause for the development of skin 
cancer, which comprises histologically distinct skin neoplasms. These include squamous cell 
carcinoma (SCC), basal cell carcinoma (BCC) and melanoma that are named after the types 
of skin cell from which they arise. Among these, SCC is the most common and invasive type 
of non-melanoma skin cancer, with limited treatment options at present, especially for the late 
stage (reviewed by Zhang and Selim, 2012). As JNK proteins, also termed stress-activated 
protein kinases (SAPKs), are highly responsive to UV radiation (Derijard et al., 1994), it is not 
surprising that hyper-activation of JNKs is frequently observed in SCC. Early studies on this 
topic revealed opposite functions for JNK1 and JNK2 in regulating skin carcinogenesis 
(reviewed by Zhang and Selim, 2012). Using a well-characterized multi-stage model of mouse 
skin carcinogenesis in which tumors are initiated with DMBA (7,12-
dymethlybenz(a)anthracene and promoted with TPA (12-O-tetradecanoylphorbol-13-acetate), 
Dong and colleagues found that in JNK2-deficient mice the multiplicity of papillomas induced 
by TPA was lower than that in wild-type mice, indicating that JNK2 is a crucial tumor promoter 
of skin cancer development (Chen et al., 2001). Moreover, Mkk4 deficiency prevented 
DMBA/TPA-induced skin cancer by suppressing JNK2 expression, providing the first clear 
evidence that the MKK4-JNK2 axis is essential for tumour formation in the skin (Finegan and 
Tournier, 2010). In contrast, JNK1 appears to be a crucial suppressor of skin cancer as JNK1-
deficient mice exhibited a significantly higher papilloma incidence compared with the wild-type 
mice (She et al., 2002). This was further confirmed by studies using the regenerated human 
SCC model, in which primary keratinocytes were transduced for expression of constitutively 
active JNK1 or JNK2 along with the oncogenic Ras mutant and then used for human skin 
regeneration on immunodeficient mice (Ke et al., 2010). While tissue expressing JNK2 were 
hyper-proliferative and displayed clinical features of human SCC, tissue expressing JNK1 
exhibited normal histological features of human skin. This indicates that JNK2, but not JNK1 
cooperates with Ras to transform normal epidermal cells to malignancy with SCC features (Ke 
et al., 2010). In line with these findings, analyses of both biopsies and keratinocytes from 
patients with SCC reported increased levels of JNK2 activity as compared to healthy controls 
(Zhang et al., 2007; Ke et al., 2010). The exact mechanism for the distinct functions of JNK1 
and JNK2 in skin cancer development is not fully clear but has been proposed to include 
ERKs and Akt signallings and the AP-1 DNA binding activity (She et al., 2002).  
More recently, JNK1 has been shown to prevent skin cancer via a novel mechanism. 
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irradiation, JNK1 associates with and phosphorylates the cell cycle inhibitory kinase Myt1, 
which induces caspase-3 cleavage and DNA fragmentation resulting in apoptosis. Knockdown 
of Myt1 suppresses UV-induced apoptosis in skin cancer cells, and Myt1 has been shown to 
phosphorylate the mitotic kinase cdc2 on tyrosine 15, which is a key site for kinase inactivation 
(Choi et al., 2009). The opposite functions of JNK1 and JNK2 in skin cancer suggest that 
therapeutics discriminating between JNK1 and JNK2 proteins may offer a promising 
therapeutic opportunity. 
 
Brain tumors 
The most frequent primary brain tumors in adults are gliomas, which begin in the glial tissue. 
Indeed, gliomas account for about 70% of adult malignant primary brain tumors. According to 
the World Health Organizzation (WHO) classification system gliomas are further distinguished 
into three subtypes: grade 2 (low-grade astrocytoma, oligodendroglioma and 
oligoastrocytoma), grade 3 (anaplastic gliomas) and grade 4 (glioblastoma) (Li et al., 2008). 
Approximately half of all gliomas are glioblastoma, by far the most severe and aggressive 
subtype (Ricard et al., 2012). A number of cellular and xenograft studies revealed a role for 
JNKs in the development and progression of gliomas. For example, elevated levels of JNKs 
activity were observed in a panel of glioblastoma cell lines and in human glioblastoma tumor 
samples (Antonyak et al., 2002). Similarly, phosphorylation of JNKs and c-Jun has been 
shown to strongly correlate with the histological grade of glioblastoma (Li et al., 2008). 
Compared to JNK1 and JNK3, JNK2 has a dominant pro-tumorigenic role in glioblastoma. 
Tsuiki et al. (2003) reported that JNK2 possesses autophosphorylation activity and constitutive 
substrate kinase activity. This is in line with data showing that JNK2 is the major JNK protein 
that is constitutively activated in glioblastoma. JNK2 was also shown to support tumorigenesis 
in vivo by activating Akt and up-regulating the expression of eukaryotic translation initiation 
factor 4 (eIF4E) (Cui et al., 2006), which is frequently overexpressed in many human cancers 
(Graff et al., 2008). More recent evidences indicate a role for JNKs in maintaining glioma stem 
cell properties, which are responsible for the poor prognosis of glioblastoma patients. Elevated 
levels of the phosphorylated (active) form of JNKs were observed in sphere-cultured U87 and 
U373 glioma cells and in stem cells isolated from patient-derived glioma cells. 
Pharmacological inhibition of JNKs with SP600125 or knockdown of JNK1 or JNK2 
significantly suppressed sphere formation, soft-agar colony formation, which are assay 
methods to evaluate stemness of stem-like cancer cells in vitro, and reduced the expression of 
stem cell markers in sphere-cultured glioma cells. Moreover, knockdown of JNK2 in glioma 
stem cells suppressed tumor formation in vivo (Yoon et al., 2012). The same group reported 
that JNK2 promotes stemness of glioma stem-like cells through up-regulation of Notch-2 
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expression (Yoon et al., 2012). This study reveals a new tumorigenic function for JNKs, in 
particular JNK2. However, there is also evidence supporting a role for JNK3, expression of 
which is largely restricted to the brain, as a tumor suppressor. Indeed, loss of expression of 
the jnk3 gene has been identified in 10 of the 19 human brain tumor cell lines examined 
(Yoshida et al., 2001). 
 
JNKs IN HEMATOLOGICAL MALIGNANCIES 
While the roles of JNK proteins in solid tumors have been described in recent studies, the 
specific functions of JNKs in hematological malignancies remain limited. This stems in part 
from a lack of genetic animal models of these conditions, which makes the task even more 
difficult.  
 
Leukemia 
Leukemia is a broad term used to describe numerous cancers of the blood and bone marrow 
(Murati et al., 2012). These hematological malignancies are characterized by an increase in 
white blood cell proliferation, coupled with the failure of normal pro-apoptotic responses to 
neoplastic cells. Leukaemia is clinically and pathologically classified as ‘acute’ and ‘chronic’. 
Additionally, these conditions are further divided according to which kind of blood cell is 
affected, such as lymphoblastic leukemia and myeloid leukemia. Acute myeloid leukemia 
(AML) is a heterogeneous clonal disorder of hemopoietic progenitor cells (“blasts”), which lose 
the ability to differentiate normally and to respond to normal regulators of proliferation 
(reviewed by Estey and Döhner, 2006). Chronic myeloid leukemia (CML) conversely involves 
the unregulated proliferation of more differentiated mature hematopoietic cells (reviewed by 
Deininger et al., 2000).  
 
One proposed therapeutic strategy for treatment of leukemia is to induce differentiation of 
circulating leukemia cells. This is a first step to induce apoptosis of these neoplastic cells. The 
precise mechanism that triggers the activation of apoptosis in mature differentiated cells has 
not been elucidated. JNK has been shown to enhance monocytic differentiation of human 
leukemia cells induced by 1,25-dihydroxyvitamin D3, a derivate of vitamin D3 (Wang et al., 
2005). Yet, the precise molecular mechanism of how JNK promotes differentiation is not 
completely understood. Recent studies have highlighted the distinct role of JNK1 and JNK2 in 
this differentiation process and described for the first time a negative interplay between JNK2 
and JNK1. It has been shown that while JNK2 is a negative regulator of monocytic 
differentiation, JNK1 is a positive regulator. Strikingly, silencing of JNK2 increased the activity 
of JNK1p46, which is associated with increased cellular differentiation after treatment with 
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1,25D. In contrast, silencing of JNK1 reduced the intensity of 1,25D-induced differentiation, 
and partially abrogated activation of c-Jun/AP-1 transcription factors (Chen-Deutsch et al., 
2009). Accordingly, specific inhibitors of JNK2, and not JNK1, may complement the 
differentiation therapy induced by the vitamin D3 derivatives and, thus, may be used as an 
anti-leukemia drug.  
 
Constitutive activation of JNK has been also found in T-cell acute lymphoblastic leukemia (T-
ALL). Suppression of JNK activity in T-ALL cells by using general (pan)-JNK chemical 
inhibitors promoted cell cycle arrest and apoptosis and increased sensitivity to Fas-mediated 
apoptosis, whereas constitutive activation of JNK in T-ALL cells resulted in accelerated cell 
cycle progression and resistance to Fas-mediated apoptosis. Silencing of JNK1, but not JNK2, 
exhibited similar effects to JNK inhibitors, suggesting that JNK1 is the predominant form of 
JNK proteins and, in this case, the identification of JNK1-specific inhibitors may have some 
important therapeutic implications in the treatment of T-ALL (Cui et al., 2009). 
 
Other studies have demonstrated that JNK activity has been also associated with treatment 
failure in AML. Biochemical analyses of primary AML bone marrow samples have shown that 
JNK activity is associated with increased efflux activity of the multi-drug protein (MRP), whose 
function promotes the efflux of chemotherapeutic drugs from the treated cells, with 
consequential resistance to chemotherapy and hyper-proliferation of AML cells. A central 
cellular program involving the signaling pathway JNK!c-Jun/AP-1 might coordinate the 
expression of MRP, thus affecting the multidrug-resistant state of AML cells (Cripe et al., 
2002). Notably, the involvement of JNK in multi-drug resistance has been also characterized 
in other human cancers (Yan et al., 2010; Ronaldson et al., 2010). However, there is no clear 
understanding of how JNK regulates the functioning of MRP, or any other member of the ATP-
binding cassette family of membrane efflux pumps.  
 
In summary, studies to precisely identify the specific function of JNK in certain type of 
leukemia cells may provide valuable information for the design of new inhibitors with clinical 
translational potential.  
 
Multiple myeloma 
Multiple myeloma (MM) is a malignant tumor of terminally differentiated B cells, characterized 
by accumulation of clonal, long-lived plasma cells in the bone marrow and extra-medullary 
sites. Notable characteristics of myeloma cells include a low proliferative capacity of plasma 
cells and the failure of normal apoptotic index in vivo. Accordingly, pro-survival mechanisms 
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play central roles in the accumulation of the malignant clones in MM. Although the role of JNK 
signaling in the pathogenesis of MM has been extensively addressed, the function of JNK in 
promoting or suppressing MM is still a debate. Initial studies from Anderson and colleagues 
described the biologic effect of JNK inhibition in MM cell lines. JNK-specific inhibitor 
SP600125 induces growth arrest of MM cell lines. Importantly, SP600125 induces activation of 
the transcription factor NF-κB and its upstream molecules IKKα, suggesting that JNK may 
play a role in the survival of MM cells by suppressing constitutive activation of NF-κB in MM 
cells (Hideshima T et al., 2003a). However, these results are conflicting with the fact that NF-
κB is important for the survival of these cancer cells (reviewed by Gilmore, 2007). Constitutive 
activation of NF-κB was indeed highly scored in CD138+ cells from the bone marrow of 22 
MM patients. In contrast to MM patients, activated forms of NF-κB were absent in cells from 
healthy individuals (Bharti et al., 2004). Diverse genetic aberrations accumulated in many 
myeloma samples activate both the canonical and alternative pathways of NF-κB activation 
(Annunziata et al., 2007; Keats et al., 2007; Hideshima et al., 2009). A possible explanation for 
this apparent discrepancy is that the JNK inhibitor SP600125 might over-stimulate NF-κB 
signaling independently of JNK activation. Whichever is the case, the molecular mechanisms 
elucidating how JNK promotes survival of MM cells are not clear (discussed below).  
 
Although the function of JNK has been linked to MM cell survival, JNK activation is also 
required for apoptotic cell death of MM cells induced by chemotherapeutic drugs. The 
proteasome inhibitor Bortezomib (originally named PS-341) has proven successful for the 
treatment of relapsed and newly diagnosed MM. Notably, Bortezomib mediates anti-MM 
activity by inducing p53 and MDM2 protein expression; it induces the phosphorylation of p53 
protein and activation of JNK activity, which is essential for the induction of caspase-3 
activation and therefore apoptosis of MM cells. In addition, SP600125 blocked bortezomib-
induced apoptosis in MM cells (Hideshima et al., 2003b).  
How can one signal pathway mediate two very different cellular responses? One plausible 
answer is that distinct JNK proteins, JNK1 and JNK2, may serve different functions in MM by 
regulating specific downstream effectors. Recently, we systematically assessed the functional 
roles of JNK1 and JNK2 in MM by silencing the expression of either JNK1 or JNK2 in MM cell 
lines and examined their activity in MM primary tumors. Interestingly, we evaluated the level of 
phospho-active JNK in myeloma plasma cells of BM trephine biopsies of newly diagnosed MM 
patients compared to normal plasma cells from tonsillar samples, and found that JNK is 
constitutively active in MM plasma. In addition, we observed that phosphorylation of JNK2 was 
significantly higher than JNK1 in a panel of MM cell lines and primary CD138+ MM cells, 
suggesting a pathogenic role for JNK2 in this disease. Silencing JNK2 enhanced MM 
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apoptotic cell death. On the other hand, ablation of JNK1 did not alter the proliferation rate of 
MM cells. More fascinating was the observation that silencing of JNK2 in MM cells was 
associated with increased JNK1 activity, and that suppression of JNK1 activity in JNK2-
depleted cells restored the regular growth rate of these malignant cells, suggesting that JNK2 
controls basal JNK1-mediated pro-apoptotic responses to abnormal signals (Barbarulo et al., 
2012). It is important to point out that the JNK2-mediated control of JNK1 activity is not a novel 
concept documented in tumorigenesis. In a range of human cell lines, it was shown that JNK1 
is actively pro-apoptotic but is constitutively inhibited by the presence of active JNK2 (Ahmed 
and Milner, 2009). Moreover, JNK2 antagonizes the JNK1-mediated differentiation signal in 
human myeloid leukemia cells resistant to vitamin D (Chen-Deutsch et al., 2009). This 
regulation of JNK1 by JNK2, however, was not observed in non-malignant cells (Ahmed and 
Milner, 2009), suggesting that the opposing roles of JNK1 and JNK2 may exist only in 
cancerous cells. Indeed, ablation of Jnk2 gene in JNK1+/+ MEFs caused increased expression 
of c-Jun and cellular proliferation (Sabapathy et al., 2004; Tournier et al., 2000), whereas 
selective inhibition of JNK2 activity by a chemical genetic approach in JNK1+/+ MEFs caused 
no changes in c-Jun expression or proliferation, suggesting compensatory increases in JNK1 
function (Jaeschke et al., 2006). Interestingly, it has also been proposed that increased JNK1 
function detected in JNK2-/- MEFs are primarily due to a competition between JNK1 and JNK2 
for activation by the upstream MAPKK (Jaeschke et al., 2006). 
 
How JNK2 suppresses the JNK1-mediated pro-apoptotic signal in MM? By investigating the 
mechanisms for the distinct role of JNK1 and JNK2 in MM, we identified and characterized a 
novel signaling pathway that involves JNK2-PARP14-JNK1 (Barbarulo et al., 2012). Previous 
studies have established that PARP14 is an ADP ribosyl-transferase that transduces survival 
signals in murine primary B cells by regulating expression of B-cell survival factors as well as 
by repressing an apoptotic program involving caspases (Goenka et al., 2009). In the mouse, 
PARP14 has been shown to facilitate B-lymphoid tumorigenesis driven by oncogenic c-Myc 
(Cho et al., 2011). Our recent study has investigated whether expression of PARP14 is under 
control of JNK2 in promoting survival of malignant MM cells. Silencing of JNK2 reduced the 
levels of PARP14 protein and promoted apoptosis in a panel of MM cell lines. Notably, ectopic 
expression of PARP14 in JNK2-depleted MM cells restored the levels of PARP14 similar to 
those of the endogenous protein expressed in MM cells, and rescued cells from undergoing 
apoptosis induced by the permanent deficiency of JNK2 expression. Moreover, the rescue of 
JNK2-depleted cells by ectopic expression of PARP14 is associated with the suppression of 
JNK1 activity in MM cells. Clearly, these data indicate that JNK2 regulates expression of 
PARP14, which is important for the suppression of JNK1 activity. However, how this regulation 
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occurs is not determined yet. It is plausible that JNK2 cooperates with certain transcription 
factors. To date, however, the identity of the transcription factors regulating Parp14 gene 
expression is not known. Moreover, regulation of PARP14 by JNK2 does not explain the 
constitutive inhibition of JNK1-mediated apoptosis in MM cells. In an attempt to evaluate how 
JNK2-PARP14 suppresses JNK1 activity, we have examined whether PARP14 protein is able 
to interact with either JNK1 or JNK2 in cells. Remarkably, we showed that PARP14 
specifically interacts with JNK1, through its C-terminal portion, thus inhibiting JNK1 kinase 
activity and ultimately apoptosis. Although at the present it is not directly proved whether JNK1 
kinase inactivation by PARP14 involves the enzymatic activity of PARP14, our data suggest 
that this might be the case. The JNK1 kinase activity is, indeed, enhanced after treatment of 
MM cells with PJ-34, a pan-inhibitor of PARP enzymatic activity (reviewed by Jagtap and 
Szabó, 2005; Barbarulo et al., 2012). However, whether this over-activation of JNK1 is due to 
specific inhibition of PARP14 enzymatic activity remain to be elucidated. In summary, we 
identify a novel pathway whereby constitutively active JNK2 promotes survival of myeloma 
cells via PARP14, which in turn associates with JNK1 and suppresses its kinase activity, 
suggesting that JNK2-PARP14 is a potential therapeutic target in myeloma. 
 
Lymphoma 
Bcr-Abl is a chimeric oncogene generated by the translocation of sequences from the c-Abl 
protein-tyrosine kinase gene on chromosome 9 into the Bcr gene on chromosome 22. Bcr-Abl 
is an activator of several signal transduction pathways that mediates malignant transformation 
and entry of the cell cycle, and is also a potent inhibitor of cell death (Cilloni and Saglio, 2012). 
Previous studies have demonstrated that survival signaling of Bcr-Abl-transformed B 
lymphoblasts is mediated by JNK1, as knockdown of Jnk1 gene in mice causes defective 
transformation of pre-B cells by Bcr-Abl. The JNK1-mediated survival is supported via 
regulation of Bcl2 expression. Notably, ectopic expression of Bcl2 rescued the defective 
phenotype of Jnk1-/- B-cells (Hess et al., 2002). These data are consistent with a model 
whereby JNK1-Bcl2 mediates the pathogenesis of transformed pre-B cells. In line with this 
observation, it was demonstrated that JNK signaling via Egr-1 and c-Myc activation is required 
for survival and proliferation of B-lymphoma cells (Gururajan et al., 2005). Suppression of JNK 
activity by SP600125 strongly inhibited cell growth in a panel of murine and human B 
lymphoma cells, indicating that JNK is essential for suppression of basal apoptosis (Gururajan 
et al., 2005). Recent observations by Sabapathy and colleagues, however, underscored the 
redundant function of JNK1 and JNK2 in B cell lymphomas (Anbalagan and Sabapathy, 
2012). These authors used the murine Eµ-Myc-induced B cell lymphoma model to induce 
lymphomagenesis and investigate the role of JNK1 and JNK2 in the development of B cell 
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lymphoma. The Eµ-Myc transgenic mice model resemble the MYC/Ig t(8:14) translocation in 
human Burkitt lymphoma where c-Myc is overexpressed in B lymphocytes by the 
immunoglobulin heavy chain enhancer (Eµ) (Adams et al., 1985). In this model, Myc-induced 
lymphoma is preceded by a prolonged pre-cancerous phase in which the high proliferative 
rates of Eµ-Myc B cells are counterbalanced by a high apoptotic index (Maclean et al., 2003). 
Surprisingly, the overall survival of Myc-transgenic mice deficient for Jnk1 is not significantly 
different from wild-type mice, and there is also no significant difference between the wild-type 
and Jnk2-/- group. Moreover, loss of either Jnk1 or Jnk2 in Myc-transgenic mice neither 
revealed any statistical difference in the survival of these two groups of animals nor 
appreciably affected the maturation status of B220+ B cells. Therefore, JNK1 or JNK2 alone is 
not dispensable for Myc-induced lymphomagenesis (Anbalagan and Sabapathy, 2012). 
Although in our study we have characterized only one B-lymphoma cell line, our observations 
are in line with this latter findings suggesting that JNK1 and JNK2 play redundant roles in B 
lymphoma cells, and the absence of either JNK1 or JNK2 is compensated for by the other 
remaining JNK isoforms for the proliferation of B lymphoma cells (Barbarulo et al., 2012). 
These observations, therefore, suggests that JNK plays an important role in B-cell lymphoma 
pathogenesis and targeting the catalytic activities of both JNK1 and JNK2 would be beneficial 
for the treatment of these conditions.  
 
STRATEGIES TO TARGET THE JNK PROTEINS 
Clearly the JNKs play key roles in the pathobiology of many cancer types. This information 
has stimulated both the academic research community and the pharmaceutical industry to 
design, synthesize and screen chemical libraries of compounds that can act as selective 
inhibitors of the JNKs. Based on their mode of action, the majority of these compounds can be 
classified into two categories, adenosine triphosphate (ATP)-competitive inhibitors and ATP-
noncompetitive inhibitors (reviewed by Siddiqui and Reddy, 2010).  
Well-recognized and thoroughly studied the ATP-competitive JNK inhibitors, include small 
molecules from a variety of scaffolds such as indazoles, aminopyrazoles, aminopyridines, 
pyridine carboxamides, benzothien-2-ylamides and benzothiazol-2-yl acetonitriles, quinoline 
derivatives, and aminopyrimidines (LoGrasso and Kamenecka, 2008; Gaillard et al., 2005; 
Szczepankiewicz et al., 2006; Kamenecka et al., 2009; He et al., 2011; Plantevin Krenitsky et 
al., 2012). Although, to date, use of these inhibitors clinically has not been reported, efficacy of 
a subset of these molecules has been explored in cell-based experiments and animal models 
of disease. For example, the anthrapyrazolone SP600125, one of the earliest and most 
studied ATP-competitive JNK inhibitor (Bennett et al., 2001) has been efficacious in mouse 
model of Parkinson disease (Wang et al., 2004). Another compound, the benzothiazolone 
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AS601245, has been shown to provide neuroprotective effects in rats after focal cerebral 
ischemia (Carboni et al., 2004) and be effective in ischemia reperfusion injury (Ferrandi et al., 
2004). These inhibitors, however, display poor kinase specificity as they target the highly 
conserved ATP-binding site. For example, SP600125 displays action against all three JNK 
proteins, and at higher concentrations, also displays ability to inhibit the closely related ERKs 
and p38 MAPKs (Bennett et al., 2001; Bain et al., 2003). Likewise, AS601245 inhibits 
phosphorylation of c-Jun at high doses, which is due to a moderately specificity for JNKs 
(Gaillard et al., 2005). To overcome the specificity problem, Zhang et al. (2012) have very 
recently developed and characterized a potent and irreversible inhibitor of all three JNK 
proteins, JNK-IN-8, that forms a covalent bond with a conserved cysteine in the ATP site. This 
has been achieved through the use of structure-based drug design. The major advantage of 
cysteine-directed covalent inhibitors is the ability to control kinase selectivity and prolong 
pharmacodynamics despite competition with high endogenous levels of ATP. It will be of 
interest to see how this novel inhibitor of JNK activity is broadly applied in the treatment of a 
range of JNK-associated diseases, including cancer, and whether desired therapeutic 
outcomes would be achieved without unwanted side effects.  
 
Alternative strategy for the inhibition of JNKs is the development of peptide or small molecule 
ATP-noncompetitive inhibitors that prevent the protein-protein interactions of JNKs with the 
JNK-interacting protein-1 (JIP1), or with the upper kinases or downstream substrates 
(Bogoyevitch et al., 2010). JIP1 is a “scaffolding” protein that enhances JNK signaling 
specificity and efficiency by bringing JNKs into proximity with their upstream activators and 
substrates (Whitmarsh, 2006). The site of interaction between JNK and JIP1 contains a 
conserved consensus sequence, which is termed D-domain (Stebbins et al., 2008). Works 
have demonstrated that a peptide, pepJIP1, consisting of 11 amino acids  (153-163) derived 
from the D-domain of JIP1, inhibits JNK activity potently in vitro and exhibits noteworthy 
selectivity for JNKs with little inhibition of other MAPKs (Barr et al., 2002; Heo et al., 2004). 
The inhibitory activity of pepJIP1 relies either on the competition of this peptide with the D-
domains of substrates or upstream kinases, or on allosteric effects (Ho et al., 2003; Barr et al., 
2002; Heo et al., 2004). Moreover, Ngoei et al. (2011) have recently reported the 
characterization of a novel JNK inhibitory peptide PYC71N, which prevents the interaction of 
JNK with c-Jun and represents a novel tool to explore the JNK-mediated substrate interactions 
and phosphorylation. 
Studies in vivo using cell-permeable JIP1-based peptides have also shown effective inhibition 
of JNK signaling. For example, the intraperitoneal administration of pepJIP1 fused to HIV-TAT 
(human immuno-deficiency Virus-Trans-acting activator of transcription) sequence in diabetic 
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mice models restores normoglycemia without causing hypoglycemia in lean mice (Kaneto et 
al., 2004). Other example of the use of JIP1-based peptides for JNKs inhibition includes a cell-
permeable and protease-resistant peptide, D-JNKI-1, which was initially found to protect 
against cerebral ischemia in two models of middle cerebral artery occlusion (Borsello et al., 
2003). Systemic intraperitoneal administration of D-JNKI-1 in mice attenuated the growth of 
B16-Fluc murine melanoma xenografts and cancer pain (Gao et al., 2009). The same inhibitor 
suppressed tumor growth of subcutaneously implanted HCC cells in nude mice and in mice 
with DEN-induced liver cancer. Immunohistochemical analysis of excised tumors confirmed 
that the anti-growth efficacy resulted from inhibiting levels of activated JNK (p-JNK) in the 
treatment group remained inhibited 3 months after D-JNKI-1 injection, whereas tumors from 
the control group continuously expressed high levels of p-JNK (Hui et al., 2008). Most 
recently, two separate studies have shown that the inhibition of the JNK activity by D-JNKI-1 in 
vivo is an effective approach to the treatment of inflammatory bowel diseases. (Reinecke et 
al., 2012; Kersting et al., 2013).  
Thus, cell-permeable JIP1-based peptides have been proven to have beneficial effects to 
improve a number of JNK-dependent diseases, although there are several challenges that 
have limited the development of peptide-based inhibitors. Other chemical entities that have 
the ability to disrupt the interaction between JNKs and JIP1 both in vitro and in vivo have also 
recently been identified (Bogoyevitch et al., 2010). In screening 30,000 small molecules in a 
Dissociation Enhanced Lanthanide Fluoro-Immuno Assay (DELFIA) platform combined with a 
Time-Resolved Fluorescence Energy Transfer (FRET) based kinase assay, Stebbins et al. 
(2008) have identified the inhibitor BI-78D3, which was found to compete with pepJIP1 for 
binding to JNKs and inhibit the JNK kinase activity. The authors have also shown that BI-78D3 
in vivo blocks concanavalin A-induced-liver damage and restores insulin sensitivity in a mouse 
model of type 2 diabetes. Moreover, through an extensive structure-based virtual screening 
Ngoei et al. (2013) have recently identified a thiazole-2,2’ diamine compound, JD123, which 
binds to both the ATP-binding site and the protein substrate site and so functions as a dual 
inhibitor of the JNK proteins. JD123 has also been shown to inhibit sorbitol-induced cJun 
phosphorylation in MEFs in a dose-dependent manner. Further structural-based studies will 
be necessary to improve membrane permeability for its use in cell and in vivo studies as well 
as to determine the precise docking modes and interactions with JNKs and so provide further 
understanding of its inhibitory mechanisms (Ngoei et al., 2013). 
 
In the cancer setting, however, the strategy of using JNK inhibitors that do not display 
selectivity across JNK proteins may be flawed as JNK1 and JNK2, which are more ubiquitous 
than JNK3 in their tissue distribution, appear to have opposite functions based on tissue 
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specificity (Yao et al., 2009; Chen et al., 2001; She et al., 2002; Chen-Deutsch et al., 2009; 
Barbarulo et al., 2012). JNK2 is constitutively activated in myeloid leukemia cells, and has 
been shown to antagonize differentiation mediated by JNK1 (Chen-Deutsch et al., 2009). Yet 
JNK2 appears to be the main JNK protein involved in multiple myeloma pathobiology via 
inhibition of the pro-apoptotic activity of JNK1 (Barbarulo et al., 2012). In contrast, JNK1 
activity appears to be essential for proliferation of human HCC (Hui et al., 2008). Thus, taken 
together, the results from these studies and others (Bost et al., 1999; Chen et al., 2001; Yang 
et al., 2003; Cui et al., 2006; Chromik et al., 2007; Ke et al., 2010; Nitta et al., 2011; Yooh et 
al., 2012) suggest that highly selective JNK1 or JNK2 inhibitors are necessary for treating 
cancer. However, to date, selective inhibitors for a specific JNK protein are not yet available 
commercially. Interestingly, Kaoud et al. (2011) have recently reported the discovery of two 
potent and selective JNK2-inhibitor peptides that inhibit migration of murine mammary 
carcinoma cells. A selective inhibitor of JNK1, AV-7, has also been developed and tested in in-
vitro studies (Yao et al., 2009). Further and more extensive studies, including in-vivo 
pharmacokinetics of these compounds will be essential to validate them for drug development. 
 
In addition, JNK1 and JNK2 appear to differentially influence tumorigenesis through regulating 
distinct cellular targets or binding partners (Figure 3). Examples include the interaction of 
JNK1, but not JNK2, with the membrane-associated kinase Myt1 and the observation that 
JNK1 phosphorylates Myt1. Phosphorylated Myt1 then inhibits UVA-induced skin cancer 
development (Choi HS et al., 2009). In multiple myeloma, we recently showed that JNK2 
inhibits the pro-apoptotic activity of JNK1 through effect on PARP14 expression (Barbarulo et 
al., 2012). In sharp contrast, JNK1 deficiency impaired liver cancer formation via modulating 
expression of MYC and the CDK inhibitor p21 (Hui et al., 2008). Besides these, not many 
studies have addressed the identification of targets regulated by the individual JNK proteins 
and none have yet evaluated the therapeutic potential of their inhibition in cancer. Indeed, so 
far, most efforts to target JNK pathways in cancer focused on direct inhibition of JNKs 
themselves. In this respect, it is important to note that selective inhibition of the individual JNK 
proteins could cause adverse cellular effects and unwanted toxicity because of their relevance 
to normal cellular functions such as adaptive immunity and brain development (Waetzig and 
Herdegen, 2005). Therefore effective treatment of JNK-associated cancers will require 
maintaining a delicate balance between suppressing deleterious functions of individual JNK 
proteins and interfering with cellular physiology. Treatments aimed at inhibiting downstream 
cellular targets of a specific JNK protein in a tissue-specific manner may have better 
therapeutic efficacy and reduce adverse side effects. 
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CONCLUDING REMARKS 
Over the past two decades, JNKs have increasingly been recognized as an attractive 
molecule target for the treatment of human malignancies because they regulate a number of 
cellular processes whose deregulation has been associated with cancer (Wagner and 
Nebreda, 2009). This has triggered extensive drug discovery efforts. To date the majority of 
developed JNK inhibitors target the highly conserved ATP-binding site, although multiple steps 
in the JNK pathway could be targeted for inhibition (reviewed by Siddiqui and Reddy, 2010; 
Bogoyevitch et al., 2010). While a number of these inhibitors have been proven to work in vivo 
in animal models of disease ranging from inflammatory to neurodegenerative disorders they 
have not been translated into clinical use thus far. One of the main concerns associated with 
ATP-competitive inhibitors is the lack of specificity as they can also target other kinases thus 
generating off-target effects. Moreover, the high concentrations of intracellular ATP 
significantly reduce the efficacy of these compounds (Siddiqui and Reddy, 2010; Bogoyevitch 
et al., 2010). Small molecule and peptide-based inhibitors, that target the docking site of 
downstream substrates or the scaffold proteins, are a promising alternative to the traditional 
ATP-competitive inhibitors with the potential for improved efficacy and specificity towards the 
JNKs (Chen et al., 2009). Cell-permeable versions of these inhibitors have been successfully 
used in studies for JNK-associated disorders including cerebral ischemia (Borsello et al., 
2003), stroke, Parkinson’s disease (Kuan and Burke, 2005) and diabetes (Kaneto et al., 
2004), and are indeed of increasing interest to the research and drug discovery communities. 
A considerable additional work, however, will be clearly needed to validate these compounds 
in in-vivo studies.  
As the diverse functions of the JNK proteins in cancer are emerging, greater efforts are now 
being directed towards the development of selective inhibitors (ATP competitive or otherwise) 
that discriminate between JNK1 and JNK2 (Figure 3). However, because JNKs play a pivotal 
role in normal biological functions, direct inhibition of the JNKs themselves could also have 
undesired side effects. Indeed, one of the major challenges facing researcher is to develop 
selective inhibitors of JNKs aimed at treating different cancers based on their ability to target 
specific JNK-mediated cellular event. As research likely will inform on new downstream 
substrates or binding partners, further studies should also focus on developing substrates-
specific inhibitors, which could make an important contribution to the future alleviation of 
different types of cancer. 
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FIGURE LEGENDS 
 
Figure 1 
 
Schematic representation of the JNK signaling cascade. Like all other MAP kinases, the 
JNK signaling cascade consists of a three-component module of upstream MAP3 kinases 
(MAP3Ks) that couples the signals from the cell surface to intracellular protein effectors. 
Different MAP3Ks have been implicated in the JNK cascade, depending on the type of 
stimulus the cell receives. Once activated, MAP3Ks phosphorylate and activate components 
of the MAP2K module, such as MKK4 and MKK7, which in turn phosphorylate and stimulate 
the activity of distinct JNK isoforms through dual phosphorylation on threonine and tyrosine 
residues within a conserved Thr-X-Tyr motif. Upon activation, each JNK protein itself can 
phosphorylate serine and threonine residues on specific substrates, delivering different 
cellular activities. 
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Figure 2 
 
JNKs regulate key cellular activities involved in cancer. JNKs are activated in response to 
different extracellular and intracellular stimuli, such as oncogenes, dietary agents, obesity, 
alcohol, infectious agents and irradiation. Persistent activation of JNKs affect tumorigenesis by 
both transcription-dependent and transcription-independent mechanisms involved in cell 
proliferation, survival, transformation, inflammation, migration and suppression of cell death.  
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Figure 3 
 
Specific cellular targets of JNK1 and JNK2 in different types of cancer. A graphical 
abstract visualizing the distinct targets regulated by the individual JNK proteins. Distinct 
functions of JNK1 and JNK2 in various cancers may occur through differential regulation of 
specific substrates and/or downstream effectors. The development of inhibitors that target 
specific downstream effectors of the individual JNK proteins would provide unique 
opportunities for therapeutic interventions.  
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